Proteins and Peptides
9 November 2015
PhaseBio Announces Initiation of Phase 2a Multiple Ascending Dose Study of Once-Weekly Basal Insulin PE0139 in Type 2 Diabete9 November 2015
Preliminary Phase I Results Demonstrate Potential Utility of DARPins in Anticancer Treatment7 November 2015
Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity3 November 2015
Proteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational Vonapanitase29 October 2015
Halozyme Announces First Clinical Dosing Of Pfizer’s Rivipansel Using Enhanze™ Technology26 October 2015
Aeglea BioTherapeutics Doses First Patient in Phase 1 Study of AEB1102 for Treatment of Solid Tumors21 October 2015
FDA approves first Factor X concentrate to treat patients with rare hereditary bleeding disorder20 October 2015
Ember Therapeutics Announce Initial Positive Results From a Phase 2 Trial of BMP-7 in Patients with Moderate Osteoarthritis of the Knee19 October 2015
Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease19 October 2015
Tarsa Therapeutics’ NDA for TBRIA(TM), the First Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis, Accepted for Filing19 October 2015
La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload16 October 2015
Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting15 October 2015
Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis13 October 2015
Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia12 October 2015
Biodel Announces Removal of Partial Clinical Hold for BIOD-531 and Plans for Potential Expansion of Target Patient Population7 October 2015
Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies2 October 2015
Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study30 September 2015
Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical DystoniaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports